Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN81JB
|
|||
| Drug Name |
OPB-111077
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Rockville
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02250170) Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor. U.S. National Institutes of Health. | |||
| REF 3 | Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.